CADL

Candel Therapeutics, Inc.

Price Chart

Latest Quote

$8.31

+0.32 (+4.01%)

Current Price

Previous Close	$7.99
Open	$8.18
Day High	$8.59
Day Low	$7.93
Volume	5,534,555

Fetched: 2026-06-19T07:56:49

Stock Information

Shares Outstanding	73.27M
Total Debt	$49.27M
Cash Equivalents	$194.83M
Net Income	$-54.42M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$608.88M
EPS (TTM)	$-1.01
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$438.40M
Income	$-54.42M
Book/sh	$1.88
Cash/sh	$2.66
Employees	55

Financial Ratios

Quick Ratio	27.63
Current Ratio	28.05
Debt/Eq	35.70

Returns & Margins

ROA	-23.64%
ROE	-51.17%

Ownership

Insider Ownership	15.78%
Institutional Ownership	59.77%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	37.77
P/B	4.41

Analyst Data

Recommendation	strong_buy
Target Price	$20.29

Technical Indicators

SMA20	$8.34
SMA50	$7.52
SMA200	$5.89
RSI	50.13
ATR	0.6207

Shares Float	56.78M
Short Float	25.18%
Short Ratio	6.46
Volatility	-0.48
Rel Volume	4.03

Performance History

Week	+1.84%
Month	+8.49%
Quarter	+69.25%
6 Months	+44.77%
YTD	+52.76%
Year	+68.22%
3 Years	+425.95%
10 Years	+18.71%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$8.31	8,192,200
2026-06-17	$7.99	1,373,700
2026-06-16	$7.97	1,913,100
2026-06-15	$8.56	1,628,200
2026-06-12	$8.56	1,361,800
2026-06-11	$8.16	1,880,600
2026-06-10	$8.35	1,600,400
2026-06-09	$8.67	1,565,400
2026-06-08	$8.50	1,508,700
2026-06-05	$8.51	2,048,400
2026-06-04	$9.27	2,853,600
2026-06-03	$8.80	2,140,700
2026-06-02	$8.42	1,723,000
2026-06-01	$8.51	1,629,500
2026-05-29	$8.30	1,364,300
2026-05-28	$8.09	1,520,300
2026-05-27	$8.05	1,740,300
2026-05-26	$7.95	1,320,100
2026-05-22	$7.99	1,587,900
2026-05-21	$7.93	1,671,800
2026-05-20	$7.71	1,434,900
2026-05-19	$7.66	1,944,100

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

📰 Latest News

CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish

Stocktwits • 2026-06-05T10:23:40Z

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data

MarketBeat • 2026-05-20T15:13:00Z

Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade

Zacks • 2026-05-19T13:55:03Z

Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch

Proactive • 2026-04-29T12:36:00Z

Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409

Proactive • 2026-03-17T14:35:00Z

Candel Therapeutics strengthens balance sheet as lead cancer therapy advances

Proactive • 2026-03-12T13:33:00Z

Candel Therapeutics prices $100M public offering

Proactive • 2026-02-20T13:40:00Z

Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering

Proactive • 2026-02-19T21:36:00Z

Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term

Simply Wall St. • 2026-01-14T10:37:04Z

Candel Therapeutics announces interim data from phase 1b CAN-3110 trial

TipRanks • 2025-10-15T12:31:08Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$125,000
Operating Revenue	$0	$0	$0	$125,000
Expenses
Interest Expense	$2,119,000	$2,090,000	$2,595,000	$1,708,000
Total Expenses	$48,177,000	$33,371,000	$38,391,000	$34,799,000
Rent Expense Supplemental	$194,000	$192,000	$161,000	$184,000
Other Income Expense	$8,199,000	$-20,802,000	$966,000	$16,370,000
Net Non Operating Interest Income Expense	$1,796,000	$-1,004,000	$-514,000	$-490,000
Interest Expense Non Operating	$2,119,000	$2,090,000	$2,595,000	$1,708,000
Operating Expense	$48,177,000	$33,371,000	$38,391,000	$34,799,000
Other Operating Expenses	$-89,000	-	-	$-48,000
General And Administrative Expense	$17,770,000	$14,057,000	$13,885,000	$14,060,000
Total Other Finance Cost	-	-	-	$490,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Net Interest Income	$1,796,000	$-1,004,000	$-514,000	$-490,000
Interest Income	$3,915,000	$1,086,000	$2,081,000	$1,218,000
Normalized Income	$-46,381,000	$-34,375,000	$-38,905,000	$-35,164,000
Net Income From Continuing And Discontinued Operation	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Total Operating Income As Reported	$-48,266,000	$-33,371,000	$-38,391,000	$-34,722,000
Net Income Common Stockholders	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Net Income	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Net Income Including Noncontrolling Interests	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Net Income Continuous Operations	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Pretax Income	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Interest Income Non Operating	$3,915,000	$1,086,000	$2,081,000	$1,218,000
Operating Income	$-48,177,000	$-33,371,000	$-38,391,000	$-34,674,000
Per Share
Diluted EPS	$-0.72	$-1.74	$-1.31	$-0.65
Basic EPS	$-0.72	$-1.74	$-1.31	$-0.65
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-43,417,000	$-31,295,000	$-35,350,000	$-32,678,000
Total Unusual Items	$8,199,000	$-20,802,000	$966,000	$16,370,000
Total Unusual Items Excluding Goodwill	$8,199,000	$-20,802,000	$966,000	$16,370,000
Reconciled Depreciation	$845,000	$990,000	$960,000	$778,000
EBITDA (Bullshit earnings)	$-35,218,000	$-52,097,000	$-34,384,000	$-16,308,000
EBIT	$-36,063,000	$-53,087,000	$-35,344,000	$-17,086,000
Diluted Average Shares	$52,958,644	$31,675,076	$28,935,289	$28,823,480
Basic Average Shares	$52,958,644	$31,675,076	$28,935,289	$28,823,480
Diluted NI Availto Com Stockholders	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Gain On Sale Of Security	$8,199,000	$-20,802,000	$966,000	$16,370,000
Research And Development	$30,496,000	$19,314,000	$24,506,000	$20,787,000
Selling General And Administration	$17,770,000	$14,057,000	$13,885,000	$14,060,000
Other Gand A	$8,944,000	$5,846,000	$4,395,000	$4,262,000
Insurance And Claims	$988,000	$1,188,000	$1,597,000	$2,384,000
Rent And Landing Fees	$194,000	$192,000	$161,000	$184,000
Salaries And Wages	$7,644,000	$6,831,000	$7,732,000	$7,230,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$51,922,000	$66,327,000	$12,745,000	$47,714,000
Total Assets	$125,195,000	$106,866,000	$41,201,000	$77,691,000
Total Non Current Assets	$3,806,000	$3,062,000	$4,404,000	$5,746,000
Other Non Current Assets	$503,000	$329,000	$382,000	$266,000
Current Assets	$121,389,000	$103,804,000	$36,797,000	$71,945,000
Other Current Assets	$1,658,000	$1,150,000	$1,384,000	$1,887,000
Cash Cash Equivalents And Short Term Investments	$119,731,000	$102,654,000	$35,413,000	$70,058,000
Cash And Cash Equivalents	$119,731,000	$102,654,000	$35,413,000	$70,058,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$49,034,000	$13,471,000	$22,762,000	$22,800,000
Long Term Debt And Capital Lease Obligation	$48,589,000	$3,010,000	$13,356,000	$22,336,000
Long Term Debt	$47,130,000	$2,603,000	$12,383,000	$20,850,000
Current Debt And Capital Lease Obligation	$445,000	$10,461,000	$9,406,000	$464,000
Current Debt	-	$9,895,000	$8,893,000	-
Other Current Borrowings	-	$9,895,000	$8,893,000	-
Liabilities
Total Liabilities Net Minority Interest	$73,273,000	$40,539,000	$28,456,000	$29,977,000
Total Non Current Liabilities Net Minority Interest	$64,276,000	$3,010,000	$14,272,000	$24,362,000
Derivative Product Liabilities	$15,598,000	$0	$916,000	$1,882,000
Non Current Deferred Liabilities	$89,000	$0	$0	$144,000
Current Liabilities	$8,997,000	$37,529,000	$14,184,000	$5,615,000
Other Current Liabilities	$89,000	$21,718,000	-	$48,000
Payables And Accrued Expenses	$8,463,000	$5,350,000	$4,778,000	$5,103,000
Payables	$1,129,000	$237,000	$422,000	$380,000
Accounts Payable	$1,129,000	$237,000	$422,000	$380,000
Equity
Common Stock Equity	$51,922,000	$66,327,000	$12,745,000	$47,714,000
Total Equity Gross Minority Interest	$51,922,000	$66,327,000	$12,745,000	$47,714,000
Stockholders Equity	$51,922,000	$66,327,000	$12,745,000	$47,714,000
Retained Earnings	$-230,387,000	$-192,205,000	$-137,028,000	$-99,089,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Treasury Shares Number	$122,608	$122,608	$122,608	$122,608
Ordinary Shares Number	$54,898,303	$46,810,480	$29,091,019	$28,919,810
Share Issued	$55,020,911	$46,933,088	$29,213,627	$29,042,418
Tangible Book Value	$51,922,000	$66,327,000	$12,745,000	$47,714,000
Invested Capital	$99,052,000	$78,825,000	$34,021,000	$68,564,000
Working Capital	$112,392,000	$66,275,000	$22,613,000	$66,330,000
Capital Lease Obligations	$1,904,000	$973,000	$1,486,000	$1,950,000
Total Capitalization	$99,052,000	$68,930,000	$25,128,000	$68,564,000
Treasury Stock	$448,000	$448,000	$448,000	$448,000
Additional Paid In Capital	$282,207,000	$258,511,000	$149,931,000	$146,961,000
Capital Stock	$550,000	$469,000	$290,000	$290,000
Common Stock	$550,000	$469,000	$290,000	$290,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$89,000	$0	$0	$144,000
Long Term Capital Lease Obligation	$1,459,000	$407,000	$973,000	$1,486,000
Current Capital Lease Obligation	$445,000	$566,000	$513,000	$464,000
Current Accrued Expenses	$7,334,000	$5,113,000	$4,356,000	$4,723,000
Net PPE	$3,303,000	$2,733,000	$4,022,000	$5,480,000
Accumulated Depreciation	$-3,558,000	$-3,076,000	$-2,089,000	$-1,129,000
Gross PPE	$6,861,000	$5,809,000	$6,111,000	$6,609,000
Leases	$3,008,000	$3,109,000	$3,109,000	$3,057,000
Other Properties	$3,467,000	$2,456,000	$2,755,000	$3,312,000
Machinery Furniture Equipment	$386,000	$244,000	$247,000	$240,000
Properties	$0	$0	$0	$0
Line Of Credit	-	-	-	-
Construction In Progress	-	-	-	-

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-38,898,000	$-27,039,000	$-34,701,000	$-32,716,000
Operating Activities
Operating Cash Flow	$-38,311,000	$-27,023,000	$-34,244,000	$-31,419,000
Cash Flow From Continuing Operating Activities	$-38,311,000	$-27,023,000	$-34,244,000	$-31,419,000
Operating Gains Losses	$-7,893,000	$20,802,000	$-887,000	$-16,370,000
Investing Activities
Capital Expenditure	$-587,000	$-16,000	$-457,000	$-1,297,000
Investing Cash Flow	$-560,000	$-16,000	$-280,000	$-1,297,000
Cash Flow From Continuing Investing Activities	$-560,000	$-16,000	$-280,000	$-1,297,000
Financing Activities
Issuance Of Capital Stock	$19,369,000	$101,758,000	$0	$0
Financing Cash Flow	$56,098,000	$94,280,000	$-121,000	$19,974,000
Cash Flow From Continuing Financing Activities	$56,098,000	$94,280,000	$-121,000	$19,974,000
Net Common Stock Issuance	$19,369,000	$101,758,000	$0	$0
Common Stock Issuance	$19,369,000	$101,758,000	$0	$0
Net Other Financing Charges	-	-	$-121,000	-
Other
Repayment Of Debt	$-11,733,000	$-9,167,000	$0	-
Issuance Of Debt	$47,946,000	$0	$0	$19,910,000
Interest Paid Supplemental Data	$1,280,000	$1,795,000	$2,148,000	$1,152,000
End Cash Position	$120,147,000	$102,920,000	$35,679,000	$70,324,000
Beginning Cash Position	$102,920,000	$35,679,000	$70,324,000	$83,066,000
Changes In Cash	$17,227,000	$67,241,000	$-34,645,000	$-12,742,000
Proceeds From Stock Option Exercised	$516,000	$1,689,000	$0	$64,000
Net Issuance Payments Of Debt	$36,213,000	$-9,167,000	$0	$19,910,000
Net Long Term Debt Issuance	$36,213,000	$-9,167,000	$0	$19,910,000
Long Term Debt Payments	$-11,733,000	$-9,167,000	$0	-
Long Term Debt Issuance	$47,946,000	$0	$0	$19,910,000
Net PPE Purchase And Sale	$-560,000	$-16,000	$-280,000	$-1,297,000
Sale Of PPE	$27,000	$0	$177,000	$0
Purchase Of PPE	$-587,000	$-16,000	$-457,000	$-1,297,000
Change In Working Capital	$2,193,000	$346,000	$-525,000	$71,000
Change In Other Working Capital	$178,000	-	$-192,000	$67,000
Change In Other Current Liabilities	$-509,000	$-513,000	$-464,000	$-464,000
Change In Other Current Assets	$-24,000	$53,000	$-116,000	$0
Change In Payables And Accrued Expense	$3,056,000	$572,000	$-256,000	$52,000
Change In Accrued Expense	$2,254,000	$757,000	$-301,000	$1,265,000
Change In Payable	$802,000	$-185,000	$45,000	$-1,213,000
Change In Account Payable	$802,000	$-185,000	$45,000	$-1,213,000
Change In Prepaid Assets	$-508,000	$234,000	$503,000	$416,000
Other Non Cash Items	$819,000	$663,000	$666,000	$589,000
Stock Based Compensation	$3,817,000	$5,312,000	$3,091,000	$2,307,000
Asset Impairment Charge	$90,000	$41,000	$390,000	$0
Depreciation Amortization Depletion	$845,000	$990,000	$960,000	$778,000
Depreciation And Amortization	$845,000	$990,000	$960,000	$778,000
Depreciation	$845,000	$990,000	$960,000	$778,000
Gain Loss On Investment Securities	$-8,199,000	$20,802,000	$-966,000	$-16,370,000
Gain Loss On Sale Of PPE	$306,000	$0	$79,000	$0
Net Income From Continuing Operations	$-38,182,000	$-55,177,000	$-37,939,000	$-18,794,000
Income Tax Paid Supplemental Data	-	-	$0	$183,000
Net Investment Purchase And Sale	-	-	-	-
Sale Of Investment	-	-	-	-
Purchase Of Investment	-	-	-	-

Fetched: 2026-06-17